NCT02771769View on ClinicalTrials.gov

Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels

TerminatedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 1, 2020

Study Completion Date

January 1, 2020

Conditions
Prostatic Neoplasms
Interventions
OTHER

blood draw

Participants will have a venous blood draw of \~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.

Trial Locations (2)

21201

University of Maryland Cancer Center, Baltimore

37212

Vanderbilt University Medical Center, Nashville

Sponsors
All Listed Sponsors
collaborator

Smerud Medical Research International AS

OTHER

collaborator

Vanderbilt University

OTHER

lead

Chronix Biomedical Corporation

INDUSTRY